Why the study?
Is fondaparinux more cost-effective than argatroban or bivalirudin for the treatment of suspected heparin-induced thrombocytopenia?
Population
Patients with suspected heparin-induced thrombocytopenia (HIT) in the United States (modeled population)
Comparison
Fondaparinux subcutaneous injection vs Argatroban or bivalirudin IV infusions
Design
Other
Authors
Loading...
May guide anticoagulant selection in HIT; leaves open need for prospective validation of modeled costs.
Is fondaparinux more cost-effective than argatroban or bivalirudin for the treatment of suspected heparin-induced thrombocytopenia?
Fondaparinux offers significant cost savings and better adverse event prevention compared to argatroban or bivalirudin for suspected heparin-induced thrombocytopenia.
Aljabri et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: